Given twice yearly, the product is planned at $40 per person annually in the 120 countries covered by Gilead’s licence. Partners expect initial supplies before the end of 2026 and broader availability in 2027.
The decision does not permit US sales, where the original medicine remains protected. National authorisations and procurement will determine actual access.
Sources 4
- FDA初步批准Dr. Reddy's每年40美元的艾滋病预防注射剂 [中文]
- U.S. FDA approves first generic injectable lenacapavir for HIV prevention [English]
- Dr Reddy's Laboratories gets USFDA tentative nod for twice-yearly HIV prevention injection [English]
- Approval of a cheap version of HIV-prevention shot lenacapavir raises hopes in low-income countries [English]